Medtronic completes acquisition of SPR, expanding patient access to minimally invasive, non-opioid treatment of chronic and acute pain

Category: Markets

Published: 2026-07-16T13:04:36.000Z

Medtronic has completed its acquisition of SPR Therapeutics, Inc. for $650 million, integrating SPR's SPRINT® PNS System into its pain therapy portfolio. This expands Medtronic's offerings for chronic and acute pain management with a minimally invasive, non-opioid treatment that does not require a permanent implant. The acquisition is expected to be minimally dilutive to Medtronic's adjusted EPS in FY27 and accretive thereafter, strengthening its leadership in healthcare technology.

Read the original source

News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.